Hazardous Drug Transport: USP 800 Rules for Houston

Most transport rules exist to protect the product. Hazardous drug transport is the category where the rules exist to protect the people who touch the package. A compounded chemotherapy dose that arrives late is a scheduling problem; the same dose that arrives leaking is an occupational exposure, a contaminated vehicle, and a documented incident. USP General Chapter <800> treats those as the same failure and writes containment requirements accordingly — and since November 1, 2023, those requirements are compendially applicable rather than informational. This guide covers what <800> actually says about moving hazardous drugs between sites, and what a Houston oncology pharmacy, infusion center, or health system should hold a courier to as a result.

What USP <800> Actually Requires in Transit

The transport language in USP General Chapter <800> is short and unusually concrete. Section 11.3 states that hazardous drugs requiring transport must be labeled, stored, and handled per applicable federal, state, and local regulations, and must be transported in containers that minimize the risk of breakage or leakage. It then draws one hard line: pneumatic tubes must not be used to transport any liquid hazardous drugs or any antineoplastic hazardous drugs, because of the potential for breakage and contamination.

Two adjacent sections carry as much operational weight. Section 11.1 requires that hazardous drugs identified as needing special handling precautions be clearly labeled at all times during their transport — not labeled at the pharmacy and then buried in an unmarked tote. Section 11.2 requires personnel to select packaging that maintains physical integrity and stability during transport, protecting the drug from damage, leakage, contamination, and degradation while protecting the workers who transport it. The chapter names the strategies it has in mind: sealed impervious plastic bags, impact-resistant and water-tight containers, capped container ports, and cautionary labeling.

For shipments leaving the entity, <800> adds a step most facilities skip: consult the Transport Information on the safety data sheet, and ensure labels and accessory labeling include storage instructions, disposal instructions, and hazard category information in a format consistent with the carrier's policies. That is a written handoff between the pharmacy's SOP and the courier's — and it is the piece that most often does not exist.

The Scope Is Wider Than Chemotherapy

Pharmacy directors tend to scope hazardous drug handling to the oncology service line. The federal list is considerably broader. NIOSH published its updated List of Hazardous Drugs in Healthcare Settings, 2024 as DHHS (NIOSH) Publication No. 2025-103, adding 25 drugs and removing seven relative to the 2016 list. Table 1 covers drugs carrying manufacturer's special handling information in the package insert and drugs meeting the NIOSH hazardous-drug definition on carcinogenicity and related criteria.

The population at risk is correspondingly large. NIOSH estimates that about 8 million U.S. healthcare workers are potentially exposed to hazardous drugs, and its list of affected roles explicitly includes shipping and receiving personnel alongside pharmacy and nursing staff. Transport is not a peripheral exposure pathway in the federal framing. It is named.

In Texas, the chapter shows up in state pharmacy rules as well. The Texas State Board of Pharmacy's sterile compounding rule, 22 TAC §291.133, names USP Chapter <800> among the USP/NF chapters applicable to a pharmacy's practice for reference-library purposes. Practically, that means a Houston pharmacy's hazardous drug SOPs — including the transport SOP — are inspection surface.

Contamination Does Not Stay Where the Drug Is Compounded

The argument for treating transport as a containment problem rather than a delivery problem comes from surface monitoring data. A long-term analysis published in the International Archives of Occupational and Environmental Health by Quartucci and colleagues in 2023 evaluated 17,693 wipe samples with a known sampling area collected between 2000 and 2021, covering platinum, 5-fluorouracil, cyclophosphamide, ifosfamide, gemcitabine, methotrexate, docetaxel, and paclitaxel.

Isolators were the most frequently contaminated location, at 24.4% of samples exceeding guidance values — expected, since that is where the drug is manipulated. The second most affected location was not a manipulation area at all. Storage areas exceeded guidance values in 17.6% of samples. And areas with no direct contact with antineoplastic drugs still exceeded guidance values in 8.9% of samples.

That last figure is the transport argument in one number. Residue moves on the outside of packages, on glove surfaces, and on the hands that carry them. A courier bag that shuttles between a compounding pharmacy and three infusion suites is exactly the kind of shared surface those studies keep finding. The mitigation is not more diligence; it is a dedicated, decontaminable, sealed outer container that never carries anything else.

Who Trained the Driver?

USP <800> applies to all personnel who handle hazardous drug preparations and all entities that store, prepare, transport, or administer them. Section 9 requires training based on job function, completed before the employee independently handles hazardous drugs, with demonstrated competency and reassessment at least every 12 months. The required curriculum includes response to known or suspected exposure and spill management.

Section 16 adds the physical requirement: spill kits containing everything needed to clean a hazardous drug spill must be readily available in all areas where hazardous drugs are routinely handled, spills must be cleaned immediately by qualified personnel in appropriate PPE, and the circumstances and management of every spill must be documented. Anyone potentially exposed during a spill or its cleanup requires immediate evaluation.

Read those together and a vehicle carrying antineoplastics on a routine route is an area where hazardous drugs are routinely handled. The question a pharmacy director should be able to answer in an inspection is simple and is usually unanswerable: who trained the driver, when was competency last reassessed, and what is in the vehicle if a vial breaks on the Katy Freeway?

Where This Breaks in Houston

Greater Houston has pushed infusion out of the hospital and across the metro. A Houston-area health system may compound in one central pharmacy near the Texas Medical Center and supply suburban infusion suites 30 to 60 minutes out in three directions, plus home infusion patients further still. Every one of those legs is a hazardous drug transport event under <800>, and each one crosses a public roadway in a metro known for sudden thunderstorms, standing water, and freeway incidents.

Consider the routine version of the failure. A dose is compounded, bagged, and handed to a general courier alongside a cooler of routine specimens and a pharmacy will-call bin. There is no dedicated outer container, no hazard label visible on the transport container, no spill kit in the vehicle, and no documented driver training. Nothing goes wrong on 199 runs. On the 200th, a hard stop on I-610 breaks a port and the residue is now in a bag that will visit two clinics before anyone notices.

The fix is structural, and it looks a lot like the segregation rules covered in our controlled substance courier compliance guide and the vehicle and driver requirements in our DOT and OSHA guide: a dedicated container, a documented SOP shared between pharmacy and courier, and evidence that the run happened the way both parties said it would. Cold-chain doses add a second constraint on top — our cold chain pharmacy delivery guide covers the temperature side of the same trip.

What to Require From a Hazardous Drug Courier

Before hazardous drug volume goes onto a transport agreement, confirm the partner can document all of the following:

1. A dedicated, impact-resistant, water-tight, decontaminable outer container used only for hazardous drugs — never shared with specimens, will-call, or supplies.
2. Hazard labeling that stays visible on the transport container for the entire trip, not only on the inner bag.
3. A written transport SOP that references your pharmacy's SOP, including the safety data sheet Transport Information for the agents actually carried.
4. A spill kit in every vehicle carrying hazardous drugs, with a named capacity limit and a written procedure for what happens when that limit is exceeded.
5. Driver training records tied to job function, completed before independent handling, with competency reassessment documented at least every 12 months.
6. A spill and exposure reporting procedure with defined notification timing to your designated person, plus immediate evaluation for anyone potentially exposed.
7. Timestamped custody at the container level, so an incident investigation can establish who held the package and when.
8. Confirmation in writing that pneumatic tube systems are never used for any leg of the route, including intra-campus transfers the courier subcontracts.
9. Coverage of the actual geography your service line runs — suburban infusion suites and home infusion addresses are where an urban-only SOP quietly stops applying.

Write these as measurable contract terms rather than assurances. Our SLA evaluation guide covers how to structure transport commitments you can audit, and our compliance page documents exactly what LabPath records on every run and — just as importantly — what it does not claim.

Key Takeaway

Hazardous drug transport is the one courier task where the person carrying the package is part of the risk model. USP <800> answers that with containment rather than care: sealed containers that survive a drop, labeling that persists the whole way, a spill kit within reach, and trained personnel whose competency is reassessed every 12 months. The surface monitoring data explains why the standard is written that way — 8.9% of wipe samples from areas with no direct drug contact still exceeded guidance values across nearly 18,000 samples. For a Houston health system compounding centrally and infusing across a 60-minute metro, that is not a pharmacy cleanroom problem. It is a routing and vendor problem, and it belongs in the transport agreement.